Jagsonpal Pharmaceuticals Limited has announced the successful allotment of 1,76,900 equity shares under its Employee Stock Option Plan 2022 (JPL ESOP 2022) to eligible employees. The allotment was completed on April 13, 2026, following the exercise of vested options by company employees.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's paid-up share capital. The following table shows the capital structure before and after the allotment:

Exercise Price Structure

The ESOP shares were allotted at three different exercise price levels, reflecting the varying grant dates and market conditions at the time of option grants:

Regulatory Compliance and Share Details

The company has fulfilled all regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly allotted shares carry distinctive numbers from 6,69,62,251 to 6,71,39,150 and will be issued in demat form.

Key regulatory aspects include:

• The shares rank pari passu with existing equity shares in all respects
• No lock-in period applies to the allotted shares
• The company's shares are listed on BSE Limited and National Stock Exchange of India Limited
• Original ESOP filing was completed in July 2022 with both exchanges

Corporate Structure

Jagsonpal Pharmaceuticals Limited, incorporated in 1978, operates from its corporate office in Gurugram, Haryana, with its registered office located in New Delhi. The company maintains additional operational presence in Mumbai, Maharashtra. The allotment was approved by the Nomination and Remuneration Committee and executed by Company Secretary Pratham Rawal.

The successful completion of this ESOP allotment demonstrates the company's commitment to employee participation in its growth story while strengthening its equity base through internal capital generation.

Jagsonpal Pharmaceuticals Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the certificate for the quarter ended March 31, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which governs the dematerialization process of securities. MCS Share Transfer Agent Limited, serving as the company's registrar and share transfer agent, provided the certification dated April 6, 2026.

Certification Confirmations

The registrar certified compliance with key dematerialization requirements for the quarter. The certificate confirms that within 15 days of receipt of securities for dematerialization:

• Securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
• Certificates have been duly verified, mutilated, and cancelled after proper verification
• The depository name has been substituted in records as the registered owner

Stock Exchange Communication

Jagsonpal Pharmaceuticals communicated the compliance filing to both major Indian stock exchanges. The company is listed on BSE Limited with scrip code 507789 and on National Stock Exchange of India Limited with the symbol JAGSNPHARM.

Corporate Information

The pharmaceutical company operates from its corporate office located at Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram, Haryana. Pratham Rawal, serving as Company Secretary and Compliance Officer, signed the regulatory filing on behalf of the company. This quarterly certification represents part of the company's ongoing regulatory compliance framework, ensuring adherence to SEBI guidelines for depositories and participants in the securities market.